Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms
Author:
Publisher
Elsevier BV
Subject
Urology,Oncology
Reference69 articles.
1. Prostate cancer: ESMO Consensus Conference Guidelines 2012;Horwich;Ann Oncol,2013
2. Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy;Gerritsen;J Clin Immunol,2012
3. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302);Rathkopf;Eur Urol,2014
4. Sipuleucel-T immunotherapy for castration-resistant prostate cancer;Kantoff;N Engl J Med,2010
5. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer;N Engl J Med,2014
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Efficacy and Safety of Programmed Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Checkpoint Inhibitors in Patients With Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis;Clinical Oncology;2024-01
2. Advances in Immunotherapy and Vaccine for Prostate Cancer;annals of urologic oncology;2023-05-27
3. Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer;Cancer Immunology, Immunotherapy;2023-03-16
4. Colorectal Cancer and Purinergic Signalling: An Overview;Cancers;2022-10-06
5. The Cellular and Molecular Immunotherapy in Prostate Cancer;Vaccines;2022-08-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3